Logo image of SNY

SANOFI-ADR (SNY) Stock Fundamental Analysis

NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD

51.98  -0.53 (-1.01%)

After market: 51.98 0 (0%)

Fundamental Rating

6

Overall SNY gets a fundamental rating of 6 out of 10. We evaluated SNY against 198 industry peers in the Pharmaceuticals industry. SNY has an excellent profitability rating, but there are some minor concerns on its financial health. SNY is valued quite cheap, while showing a decent growth score. This is a good combination! SNY also has an excellent dividend rating. With these ratings, SNY could be worth investigating further for value and dividend investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
SNY had positive earnings in each of the past 5 years.
Each year in the past 5 years SNY had a positive operating cash flow.
SNY Yearly Net Income VS EBIT VS OCF VS FCFSNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

Looking at the Return On Assets, with a value of 9.00%, SNY belongs to the top of the industry, outperforming 91.92% of the companies in the same industry.
SNY's Return On Equity of 15.37% is amongst the best of the industry. SNY outperforms 89.39% of its industry peers.
With an excellent Return On Invested Capital value of 15.58%, SNY belongs to the best of the industry, outperforming 92.42% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 42.34%.
The last Return On Invested Capital (15.58%) for SNY is above the 3 year average (7.46%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9%
ROE 15.37%
ROIC 15.58%
ROA(3y)5.07%
ROA(5y)6.23%
ROE(3y)8.63%
ROE(5y)10.88%
ROIC(3y)7.46%
ROIC(5y)7.05%
SNY Yearly ROA, ROE, ROICSNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

SNY's Profit Margin of 12.97% is amongst the best of the industry. SNY outperforms 89.90% of its industry peers.
SNY's Profit Margin has improved in the last couple of years.
The Operating Margin of SNY (22.04%) is better than 88.38% of its industry peers.
In the last couple of years the Operating Margin of SNY has grown nicely.
The Gross Margin of SNY (70.04%) is better than 77.27% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 22.04%
PM (TTM) 12.97%
GM 70.04%
OM growth 3Y0.02%
OM growth 5Y3.47%
PM growth 3Y-6.53%
PM growth 5Y12.13%
GM growth 3Y0.71%
GM growth 5Y0.58%
SNY Yearly Profit, Operating, Gross MarginsSNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

5

2. Health

2.1 Basic Checks

SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for SNY has been reduced compared to 1 year ago.
The number of shares outstanding for SNY has been reduced compared to 5 years ago.
The debt/assets ratio for SNY has been reduced compared to a year ago.
SNY Yearly Shares OutstandingSNY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
SNY Yearly Total Debt VS Total AssetsSNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

SNY has a debt to FCF ratio of 3.04. This is a good value and a sign of high solvency as SNY would need 3.04 years to pay back of all of its debts.
The Debt to FCF ratio of SNY (3.04) is better than 90.40% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that SNY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.17, SNY perfoms like the industry average, outperforming 47.98% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 3.04
Altman-Z N/A
ROIC/WACC2.17
WACC7.19%
SNY Yearly LT Debt VS Equity VS FCFSNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

SNY has a Current Ratio of 1.46. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY's Current ratio of 1.46 is on the low side compared to the rest of the industry. SNY is outperformed by 70.20% of its industry peers.
A Quick Ratio of 0.74 indicates that SNY may have some problems paying its short term obligations.
SNY has a Quick ratio of 0.74. This is amonst the worse of the industry: SNY underperforms 84.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 0.74
SNY Yearly Current Assets VS Current LiabilitesSNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

5

3. Growth

3.1 Past

SNY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.99%.
SNY shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.10% yearly.
The Revenue has grown by 30.30% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-12.99%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-53.61%
Revenue 1Y (TTM)30.3%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-12.62%

3.2 Future

SNY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.23% yearly.
The Revenue is expected to grow by 4.33% on average over the next years.
EPS Next Y8.37%
EPS Next 2Y9.02%
EPS Next 3Y8.18%
EPS Next 5Y8.23%
Revenue Next Year1.53%
Revenue Next 2Y4.25%
Revenue Next 3Y4.83%
Revenue Next 5Y4.33%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SNY Yearly Revenue VS EstimatesSNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B 40B 50B
SNY Yearly EPS VS EstimatesSNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4 5

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 13.57 indicates a correct valuation of SNY.
SNY's Price/Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 86.87% of the companies in the same industry.
When comparing the Price/Earnings ratio of SNY to the average of the S&P500 Index (25.82), we can say SNY is valued slightly cheaper.
A Price/Forward Earnings ratio of 9.99 indicates a reasonable valuation of SNY.
SNY's Price/Forward Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 85.35% of the companies in the same industry.
SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 13.57
Fwd PE 9.99
SNY Price Earnings VS Forward Price EarningsSNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

SNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNY is cheaper than 94.44% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNY is valued cheaper than 82.32% of the companies in the same industry.
Industry RankSector Rank
P/FCF 19.12
EV/EBITDA 5.2
SNY Per share dataSNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

SNY's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.62
PEG (5Y)2.66
EPS Next 2Y9.02%
EPS Next 3Y8.18%

8

5. Dividend

5.1 Amount

SNY has a Yearly Dividend Yield of 4.36%, which is a nice return.
Compared to an average industry Dividend Yield of 4.24, SNY pays a better dividend. On top of this SNY pays more dividend than 95.45% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, SNY pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.36%

5.2 History

The dividend of SNY has a limited annual growth rate of 4.34%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased recently.
Dividend Growth(5Y)4.34%
Div Incr Years1
Div Non Decr Years1
SNY Yearly Dividends per shareSNY Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

5.3 Sustainability

SNY pays out 39.72% of its income as dividend. This is a sustainable payout ratio.
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP39.72%
EPS Next 2Y9.02%
EPS Next 3Y8.18%
SNY Yearly Income VS Free CF VS DividendSNY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B
SNY Dividend Payout.SNY Dividend Payout, showing the Payout Ratio.SNY Dividend Payout.PayoutRetained Earnings

SANOFI-ADR

NASDAQ:SNY (5/23/2025, 8:00:02 PM)

After market: 51.98 0 (0%)

51.98

-0.53 (-1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-24 2025-04-24/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners39.32%
Inst Owner Change0.57%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap127.25B
Analysts80
Price Target67.56 (29.97%)
Short Float %0.16%
Short Ratio1.15
Dividend
Industry RankSector Rank
Dividend Yield 4.36%
Yearly Dividend2.14
Dividend Growth(5Y)4.34%
DP39.72%
Div Incr Years1
Div Non Decr Years1
Ex-Date05-09 2025-05-09 (2.212154)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.16%
Min EPS beat(2)-2.18%
Max EPS beat(2)14.5%
EPS beat(4)3
Avg EPS beat(4)4.59%
Min EPS beat(4)-2.18%
Max EPS beat(4)14.5%
EPS beat(8)5
Avg EPS beat(8)2.9%
EPS beat(12)8
Avg EPS beat(12)3.44%
EPS beat(16)12
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-4.57%
Max Revenue beat(2)3.66%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.5%
Revenue beat(12)6
Avg Revenue beat(12)19.16%
Revenue beat(16)10
Avg Revenue beat(16)28.08%
PT rev (1m)5.37%
PT rev (3m)11.64%
EPS NQ rev (1m)-1.4%
EPS NQ rev (3m)4.79%
EPS NY rev (1m)-1.4%
EPS NY rev (3m)1.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.59%
Revenue NY rev (1m)-3.29%
Revenue NY rev (3m)-5.16%
Valuation
Industry RankSector Rank
PE 13.57
Fwd PE 9.99
P/S 1.22
P/FCF 19.12
P/OCF 12.39
P/B 1.45
P/tB 9.84
EV/EBITDA 5.2
EPS(TTM)3.83
EY7.37%
EPS(NY)5.2
Fwd EY10.01%
FCF(TTM)2.72
FCFY5.23%
OCF(TTM)4.2
OCFY8.07%
SpS42.53
BVpS35.89
TBVpS5.28
PEG (NY)1.62
PEG (5Y)2.66
Profitability
Industry RankSector Rank
ROA 9%
ROE 15.37%
ROCE 19.55%
ROIC 15.58%
ROICexc 16.79%
ROICexgc 53.71%
OM 22.04%
PM (TTM) 12.97%
GM 70.04%
FCFM 6.39%
ROA(3y)5.07%
ROA(5y)6.23%
ROE(3y)8.63%
ROE(5y)10.88%
ROIC(3y)7.46%
ROIC(5y)7.05%
ROICexc(3y)8.27%
ROICexc(5y)7.94%
ROICexgc(3y)35.84%
ROICexgc(5y)35.27%
ROCE(3y)9.37%
ROCE(5y)8.86%
ROICexcg growth 3Y-11.4%
ROICexcg growth 5Y0.08%
ROICexc growth 3Y1.08%
ROICexc growth 5Y3.67%
OM growth 3Y0.02%
OM growth 5Y3.47%
PM growth 3Y-6.53%
PM growth 5Y12.13%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 3.04
Debt/EBITDA 0.56
Cap/Depr 89.1%
Cap/Sales 3.47%
Interest Coverage -34.57
Cash Conversion 38.03%
Profit Quality 49.3%
Current Ratio 1.46
Quick Ratio 0.74
Altman-Z N/A
F-Score7
WACC7.19%
ROIC/WACC2.17
Cap/Depr(3y)72.19%
Cap/Depr(5y)66.85%
Cap/Sales(3y)6.19%
Cap/Sales(5y)5.87%
Profit Quality(3y)111.96%
Profit Quality(5y)103.11%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.99%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-53.61%
EPS Next Y8.37%
EPS Next 2Y9.02%
EPS Next 3Y8.18%
EPS Next 5Y8.23%
Revenue 1Y (TTM)30.3%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-12.62%
Revenue Next Year1.53%
Revenue Next 2Y4.25%
Revenue Next 3Y4.83%
Revenue Next 5Y4.33%
EBIT growth 1Y21.75%
EBIT growth 3Y4.19%
EBIT growth 5Y6.9%
EBIT Next Year37.04%
EBIT Next 3Y15.5%
EBIT Next 5Y10.86%
FCF growth 1Y-18.63%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y-11.47%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%